FDA–approved and off-label recommendations for licensed tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) products — United States, 2019
January 24th, 2020
Havers FP, Moro PL, Hunter P, Hariri S, Bernstein H. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019. MMWR Morb Mortal Wkly Rep 2020;69:77–83. DOI: http://dx.doi.org/10.15585/mmwr.mm6903a5external icon
TABLE. Food and Drug Administration (FDA)–approved and off-label recommendations for licensed tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) products — United States, 2019
Licensed Tdap product |
FDA-approved indications for use and administration |
Off-label uses |
Decennial Td booster |
Tetanus prophylaxis for wound management |
Catch-up immunization,* including during pregnancy† |
Adacel§ |
Age: 10–64 years |
Age: ≥65 years |
Age: <10 or ≥65 years |
Age: 7–9 years |
Routine booster ≥5 years after a dose of DTaP or Td vaccine, with a second dose ≥8 years after first (any) Tdap dose |
Any dose beyond second Adacel dose administered ≥8 years after first Tdap dose |
>1 Tdap dose |
Tetanus prophylaxis if ≥5 years have elapsed since the last tetanus-containing vaccine |
Boostrix§ |
Age: ≥10 years |
Any dose if previously received Tdap |
Age: <10 years |
Age: 7–9 years |
Single dose ≥5 years after a dose of DTaP or Td vaccine |
Any dose if previously received Tdap |
>1 Tdap dose |
Tetanus prophylaxis if no previous Tdap |
Abbreviations: DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; Td = tetanus and reduced diphtheria toxoid.
* Persons with incomplete or unknown vaccination history should receive a single dose of Tdap, preferably as the first dose of the 3-dose catch-up series; if additional tetanus toxoid–containing doses are needed, either Td or Tdap vaccine may be used.
† Both Tdap vaccines may be administered during pregnancy with the same intervals and restrictions (vaccine specific) as would apply to a nonpregnant person.
§ Package inserts for indications and intervals for wound management are available at https://www.fda.gov/media/119862/downloadexternal icon (Adacel) and https://www.fda.gov/media/124002/downloadexternal icon (Boostrix).
This entry was posted
on
Friday, January 24th, 2020 at
1:17 pm and is filed under
FDA, Tetanus .
You can follow any responses to this entry through the
RSS 2.0 feed.
Both comments and pings are currently closed.